Molecular Landscape and Validation of New Genomic Classification in 2668 Adult AML Patients: Real Life Data from the PETHEMA Registry.
Next–Generation Sequencing
acute myeloid leukemia
clinical validation
cross–validations
genomic classification
mutational profile
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
10 Jan 2023
10 Jan 2023
Historique:
received:
22
11
2022
revised:
30
12
2022
accepted:
07
01
2023
entrez:
21
1
2023
pubmed:
22
1
2023
medline:
22
1
2023
Statut:
epublish
Résumé
Next-Generation Sequencing (NGS) implementation to perform accurate diagnosis in acute myeloid leukemia (AML) represents a major challenge for molecular laboratories in terms of specialization, standardization, costs and logistical support. In this context, the PETHEMA cooperative group has established the first nationwide diagnostic network of seven reference laboratories to provide standardized NGS studies for AML patients. Cross-validation (CV) rounds are regularly performed to ensure the quality of NGS studies and to keep updated clinically relevant genes recommended for NGS study. The molecular characterization of 2856 samples (1631 derived from the NGS-AML project; NCT03311815) with standardized NGS of consensus genes (
Identifiants
pubmed: 36672386
pii: cancers15020438
doi: 10.3390/cancers15020438
pmc: PMC9856266
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Bristol-Myers Squibb
ID : PETHEMA-NGS-LMA
Organisme : Instituto de Salud Carlos III
ID : PI18/01340
Organisme : Instituto de Salud Carlos III
ID : PI19/00730
Organisme : Instituto de Salud Carlos III
ID : PI19/01518
Organisme : Instituto de Salud Carlos III
ID : FI19/00059
Références
Hemasphere. 2022 Aug 02;6(8):e761
pubmed: 35935605
Int J Lab Hematol. 2020 Dec;42(6):849-857
pubmed: 32730663
Cancers (Basel). 2019 Feb 21;11(2):
pubmed: 30795628
Nat Commun. 2021 Dec 13;12(1):7244
pubmed: 34903734
N Engl J Med. 2016 Jun 9;374(23):2209-2221
pubmed: 27276561
Blood. 2017 Jan 26;129(4):424-447
pubmed: 27895058
Mol Oncol. 2021 Sep;15(9):2285-2299
pubmed: 34101344
Int J Mol Sci. 2018 Apr 20;19(4):
pubmed: 29677173
Front Oncol. 2021 May 03;11:659253
pubmed: 34012921
Oncotarget. 2018 May 29;9(41):26417-26430
pubmed: 29899868
Leukemia. 2019 Feb;33(2):299-312
pubmed: 30651634
Blood. 2022 Jan 6;139(1):6-7
pubmed: 34989771
Am J Hematol. 2022 Nov;97(11):1443-1452
pubmed: 36054614
Blood. 2016 Jan 7;127(1):29-41
pubmed: 26660431
Hemasphere. 2021 Jun 01;5(6):e572
pubmed: 34095756
Haematologica. 2019 May;104(5):868-871
pubmed: 30923100
Haematologica. 2017 Mar;102(3):529-540
pubmed: 28250006
Front Oncol. 2022 Jul 05;12:896426
pubmed: 35865470
Haematologica. 2018 Nov;103(11):1853-1861
pubmed: 29903761
Leukemia. 2022 Jul;36(7):1703-1719
pubmed: 35732831
J Mol Diagn. 2017 Mar;19(2):255-264
pubmed: 28017569
J Mol Diagn. 2017 May;19(3):341-365
pubmed: 28341590
Appl Transl Genom. 2016 Jul 01;10:2-9
pubmed: 27668169
Cancer Biol Med. 2016 Mar;13(1):3-11
pubmed: 27144058
J Clin Oncol. 2017 Mar 20;35(9):934-946
pubmed: 28297624
Leukemia. 2021 Mar;35(3):867-870
pubmed: 32576964
Biomark Res. 2020 May 20;8:17
pubmed: 32477567
N Engl J Med. 2013 May 30;368(22):2059-74
pubmed: 23634996
Nat Commun. 2022 Aug 8;13(1):4622
pubmed: 35941135
Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):348-355
pubmed: 27913501
Front Oncol. 2019 Sep 04;9:851
pubmed: 31552176
Blood Cancer J. 2018 Nov 12;8(11):113
pubmed: 30420667
Onco Targets Ther. 2019 Mar 11;12:1937-1945
pubmed: 30881045
Hematol Rep. 2020 Sep 21;12(Suppl 1):8957
pubmed: 33042506
Cancers (Basel). 2021 May 18;13(10):
pubmed: 34070172
Blood Adv. 2022 Jan 11;6(1):238-247
pubmed: 34448807
Haematologica. 2020 Nov 12;106(12):3079-3089
pubmed: 33179471
Leukemia. 2022 Oct;36(10):2351-2367
pubmed: 36008542
Nature. 2012 Jan 11;481(7382):506-10
pubmed: 22237025
Blood. 2022 Sep 15;140(11):1200-1228
pubmed: 35767897